Kumar Budur sold $1.7M of HRMY
CHIEF MEDICAL OFFICER at Harmony Biosciences Holdings, Inc.. 38,452 shares at an average of $43.05, traded Sep 16, 2026, filed Sep 18, 2026.
Score components
- +15RoleOfficer
- +25Trade size$1.7M at market
- +20Share of holdings soldSold 100% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002009762-26-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 16, 2026 | MOption exercise Common Stock | +900 | $30.69 | $28k | 14,015 | 25 d ago |
| Sep 16, 2026 | MOption exercise Common Stock | +900 | $30.27 | $27k | 14,915 | 25 d ago |
| Sep 16, 2026 | SOpen-market sale Common Stock10b5-1 | -1,800 | $43.01 | $77k | 13,115 | 25 d ago |
| Sep 17, 2026 | MOption exercise Common Stock | +400 | $30.69 | $12k | 13,515 | 25 d ago |
| Sep 17, 2026 | MOption exercise Common Stock | +400 | $30.27 | $12k | 13,915 | 25 d ago |
| Sep 17, 2026 | SOpen-market sale Common Stock10b5-1 | -800 | $43.00 | $34k | 13,115 | 25 d ago |
| Sep 18, 2026 | MOption exercise Common Stock | +10,406 | $30.69 | $319k | 23,521 | 25 d ago |
| Sep 18, 2026 | MOption exercise Common Stock | +25,446 | $30.27 | $770k | 48,967 | 25 d ago |
| Sep 18, 2026 | SOpen-market sale Common Stock10b5-1 | -35,852 | $43.05 | $1.5M | 13,115 | 25 d ago |
| Sep 16, 2026 | MOption exercise Stock Optionderivative | -900 | $0.00 | $0 | 29,400 | 25 d ago |
| Sep 16, 2026 | MOption exercise Stock Optionderivative | -900 | $0.00 | $0 | 63,346 | 25 d ago |
| Sep 17, 2026 | MOption exercise Stock Optionderivative | -400 | $0.00 | $0 | 29,000 | 25 d ago |
| Sep 17, 2026 | MOption exercise Stock Optionderivative | -400 | $0.00 | $0 | 62,946 | 25 d ago |
| Sep 18, 2026 | MOption exercise Stock Optionderivative | -10,406 | $0.00 | $0 | 18,594 | 25 d ago |
| Sep 18, 2026 | MOption exercise Stock Optionderivative | -25,446 | $0.00 | $0 | 37,500 | 25 d ago |
Related signals
Other insiders at Harmony Biosciences Holdings, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | Harmony Biosciences Holdings, Inc. | Kumar Budur CHIEF MEDICAL OFFICER | $1.5M 33,954 shares | -141% | |
| 18Weak | Harmony Biosciences Holdings, Inc. | Sandip Kapadia CHIEF FINANCIAL OFFICER | $139k 3,746 shares | -13% | |
| 44Moderate | Harmony Biosciences Holdings, Inc. | Sandip Kapadia CHIEF FINANCIAL OFFICER | $753k 20,961 shares | -100% | |
| 43Moderate | Harmony Biosciences Holdings, Inc. | Jeffrey M. Dayno PRESIDENT, CEO | $1.0M 25,933 shares | -130% | |
| 37Weak | Harmony Biosciences Holdings, Inc. | Sandip Kapadia CHIEF FINANCIAL OFFICER | $791k 20,000 shares | -100% | |
| 32Weak | Harmony Biosciences Holdings, Inc. | Sandip Kapadia CHIEF FINANCIAL OFFICER | $120k 3,427 shares | -100% | |
| 44Moderate | Harmony Biosciences Holdings, Inc. | Sandip Kapadia CHIEF FINANCIAL OFFICER | $787k 21,573 shares | -100% | |
| 35Weak | Harmony Biosciences Holdings, Inc. | Sandip Kapadia CHIEF FINANCIAL OFFICER | $227k 6,987 shares | -100% | |
| 11Weak | Harmony Biosciences Holdings, Inc. | Jeffrey Dierks CHIEF COMMERCIAL OFFICER | $159k 4,869 shares | -100% | |
| 34Weak | Harmony Biosciences Holdings, Inc. | Jeffrey Dierks CHIEF COMMERCIAL OFFICER | $552k 14,754 shares | -112% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.